Andrew R Steele, Connor A Howe, Travis D Gibbons, Katharine Foster, Alexandra M Williams, Hannah G Caldwell, L Madden Brewster, Jennifer Duffy, Justin A Monteleone, Prajan Subedi, James D Anholm, Mike Stembridge, Philip N Ainslie, Joshua C Tremblay
Pentoxifylline is a non-selective phosphodiesterase inhibitor used for the treatment of peripheral artery disease. Pentoxifylline acts through cyclic adenosine monophosphate, thereby enhancing red blood cell deformability, causing vasodilation and decreasing inflammation, and potentially stimulating ventilation. We conducted a double-blind, placebo-controlled, <u>crossover, counterbalanced</u> study to test the hypothesis that pentoxifylline could lower blood viscosity, enhance cerebral blood flow and decrease pulmonary artery pressure in lowlanders following 11-14 days at 3800m...
January 19, 2024: American Journal of Physiology. Heart and Circulatory Physiology